Compare Mesoblast Limited (MESO) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs ProShares Ultra QQQ ETF — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while ProShares Ultra QQQ ETF trades at $98.43 (market cap $15.38B). The key difference: ProShares Ultra QQQ ETF is far larger — about 8.8× Mesoblast Limited's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| MESO | QLD | |
|---|---|---|
Market Cap | $1.75B | $15.38B |
Volume | 239,027 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.96 | $100.77 |
52-Week Low | $13.19 | $57.16 |
Typical Hold Time | 15 Days | 36 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
QLD trades at $98.43, down 1.8% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains key support at $96 with resistance at $100. Recent news highlights QLD's resilience compared to higher-leverage alternatives during market downturns, with institutional buying activity noted in recent filings.
The outlook remains cautiously optimistic given the bullish technical setup, though investors face volatility risks from Federal Reserve policy and Nasdaq concentration. QLD's 2x leverage strategy offers a middle ground for Nasdaq-100 exposure, but requires careful risk management during market stress periods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
